Biodexa Pharmaceuticals Plc (BDRX)

NASDAQ: BDRX · USD

$2.82

+0.02 (+0.7%)· Recorded snapshot

Market cap	362.7K
Net income (ttm)	-5.9M
EPS (ttm)	-$103
Shares out	128.6K
Volume	9,232.579
Beta	1.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -5.9M
EPS (ttm): -$103
Market cap: 362.7K

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-42

P25 n/aP50 n/aP75 n/a

ROIC-138.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BDRX indicators

Market & fundamental data

Available fields

181

Groups with data

Currency

GBP

Showing 181 of 181 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001643918
Company name	Biodexa Pharmaceuticals Plc
Country	United Kingdom
Country code	US
CUSIP number	59564R864
Earnings date	2026-09-11
Earnings time	amc
Employees	11
Employees change	-2
Employees growth	-15.38%
Enterprise value	$-3.9M
Exchange	NASDAQ
Financial currency	GBP
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US59564R8640
Last 10-K release date	2026-03-27
Last earnings date	2026-09-11
Last refreshed	2026-11-04
Last stock split date	2026-10-26
Last stock split type	Reverse
Market cap	$362,745
Market cap category	Nano-Cap
Next earnings date	2027-03-29
Options	No
Price	$2.82
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	BDRX
Website	https://www.biodexapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3,634.92%
FCF / EV yield	236.5%
FCF yield	-2,557.59%
P/B ratio	0.02x
Price / tangible book value	0.08x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-533,127
ROA	-40.11%
ROA (5Y)	-47.92%
ROCE	-88.89%
ROE	-42%
ROE (5Y)	-101.9%
ROIC	-138.48%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9,405
Depreciation and amortization	$-10,749
EBIT	$-11.7M
EBITDA	$-11.7M
EPS	$-102.50
FCF per share	$-72.12
Financing cash flow	$9.2M
Free cash flow	$-9.3M
Free cash flow minus SBC	$-9.4M
Gross profit	$-6.9M
Income taxes	$137,986
Investing cash flow	$-1.2M
Net borrowing	$-708,076
Net cash flow	$-1.1M
Net income	$-5.9M
Operating cash flow minus SBC	$-9.4M
Operating income	$-11.7M
Stock-based compensation	$163,195

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$136.76
Debt / equity	0
Interest coverage	-58.15
Long-term assets	$7.9M
Long-term liabilities	$392,484
Net cash (debt)	$4.3M
Net cash / market cap	1,181.42%
Net cash growth	-30.88%
Net debt / equity	-0.34
Piotroski F-Score	0
Property, plant and equipment	$26,872
Shareholders' equity	$12.8M
Tangible book value	$4.8M
Tangible book value per share	$51.24
Total assets	$16.9M
Total cash	$4.3M
Total debt	$0
Total liabilities	$4.1M
WACC	11.31%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$9M
Current liabilities	$3.7M
Current ratio	2.41
Net working capital	$906,196
Quick ratio	2.41
Working capital	$5.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-100%
10Y return CAGR	-87.07%
10Y total return	-100%
150-day SMA	$16.62
1D price change	0.71%
1M price change	-43.13%
1M total return	-43.14%
1W price change	-28.24%
1W total return	-28.24%
1Y price change	-98.89%
1Y return CAGR	-98.89%
1Y total return	-98.89%
20-day SMA	$3.51
200-day SMA	$24.51
3M price change	-73.3%
3M total return	-73.3%
3Y price change	-99.99%
3Y return CAGR	-95.81%
3Y total return	-99.99%
50-day SMA	$5.30
50-day SMA vs 200-day SMA	50under200
52-week high	$357.60
52-week high date	2025-12-10
52-week low	$2.70
52-week low date	2026-10-13
5Y price change	-100%
5Y return CAGR	-96%
5Y total return	-100%
6M price change	-88.37%
6M total return	-88.37%
After-hours change	-6.74%
After-hours close	$2.82
After-hours price	$2.63
All-time high	$5,646,153,846.15
All-time high date	2015-12-08
All-time low	$2.70
All-time low date	2026-10-13
Average true range (ATR)	$0.62
Average volume	527.7K
Beta (1Y)	2.7
Beta (2Y)	0.95
Beta (5Y)	1.28
Change from 52-week high	-99.21%
Change from 52-week low	4.56%
Change from all-time high	-100%
Change from all-time low	4.56%
Change from open	-2.76%
Day's gap	3.57%
Dollar volume	$26,036
High price	$3.03
Low price	$2.75
Monthly RSI	26.87
Open price	$2.90
Position in 52-week range	25%
Premarket change	-2.13%
Premarket close	$2.82
Premarket price	$2.76
Premarket volume	384
Previous close	$2.80
Price vs 150-day SMA	-83.03%
Price vs 20-day SMA	-19.66%
Price vs 200-day SMA	-88.49%
Price vs 50-day SMA	-46.77%
Relative volume	0.02
RSI	35.17
Sharpe ratio	-1.33
Sharpe ratio (3Y)	-0.9
Sharpe ratio (5Y)	-1.17
Sortino ratio	-2.35
Sortino ratio (3Y)	-1.61
Sortino ratio (5Y)	-1.9
Volume	9.2K
Weekly RSI	23.79
YTD price change	-96.89%
YTD total return	-96.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	115.5K
Float percentage	89.8%
Shares held by insiders	2.15%
Shares held by institutions	0.05%
Shares outstanding	128.6K
Short % of shares	21.93%
Short ratio	0.2 days

Deeper analysis on BDRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BDRX report

Is a complete BDRX research report available?

No complete published report is available for Biodexa Pharmaceuticals Plc (BDRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Biodexa Pharmaceuticals Plc (BDRX)

Price

Financial snapshot

Fair-value bridge

Latest news · BDRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BDRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BDRX

Frequently asked questions